Form 4: Elicio Therapeutics Executive Receives Stock Grant
Insider Transaction (Form 4)
Peter Demuth, Chief Scientific Officer of Elicio Therapeutics, Inc., received 52,832 shares of common stock on July 16, 2026.
Summary
- Grant/award: acquired 52,832 Stock Option (Right to Buy) on July 16, 2026; holds 52,832 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Peter Demuth — Officer (Chief Scientific Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-16 | Grant/award | Stock Option (Right to Buy) | 52,832 | — | — | 52,832 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-16 | Grant/award (52,832 shares) |
Keywords
insider transaction, Form 4, ELTX, Elicio Therapeutics, Inc., neutral, Peter Demuth
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.